BioCentury | Oct 16, 2020
Finance

VectivBio prepping pivotal GI trial with $110M crossover round that could presage IPO

A public listing could be VectivBio’s next financial step now that it has raised $110 million in a crossover round that will fund its planned Phase III trial in short bowel syndrome, as well as...
BioCentury | Sep 30, 2020
Distillery Therapeutics

An FGF21, GLP-1 fusion protein for diabetes, obesity

...diabetes and obesity. In HEK cells, the fusion protein agonized the FGF21 receptor complex and GLP-1R...
...levels compared with FGF21 or GLP-1 monotherapy.TARGET/MARKER/PATHWAY: Fibroblast growth factor 21 (FGF21); glucagon-like peptide-1 (GLP-1); glucagon-like peptide-1 receptor (GLP-1R; GLP1R)EXPERIMENTAL...
BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
BioCentury | Sep 30, 2020
Product Development

Partner Amgen becomes investor as Carmot pushes diabetes therapies ahead with $47M series C

...Phase I/II trials for peptide-small molecule hybrid GLP-1R/GIPR...
...to read out next year, follow first-in-class GLP-1R/GIPR...
...NASH). The company is developing additional preclinical GLP-1R/GIPR...
BioCentury | Sep 25, 2020
Product Development

Novo makes obesity pick as amylin/GLP-1 combo promises gastric bypass-like efficacy

Novo Nordisk is closing in on a one-two punch it believes could shift the treatment paradigm for obesity with the pick of an amylin/semaglutide combination as its next big therapy in the disease. The combo...
BioCentury | Jul 10, 2020
Finance

How buysiders are sizing up commercial launches during the pandemic

Commercial launches were expected to be one of the biopharma activities hit hardest by the pandemic, but some new products have performed better than expected. The environment is not only pushing biotechs to new practices,...
BioCentury | Jun 19, 2020
Product Development

Hua shows sustained benefit in diabetics with glucokinase activator

...not stand out from the 0.3-0.7% and 0.6-1.16% placebo- or control-adjusted reductions reported for marketed GLP-1R...
BioCentury | Jun 11, 2020
Deals

With $725M Corvidia takeout, Novo gets clinical atherosclerosis asset

Novo Nordisk’s deal to acquire Corvidia for $725 million up front gives the Danish pharma a Phase IIb atherosclerosis asset that expands its range in cardiometabolic diseases adjacent to its core business of treating diabetes...
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...KT-A832, which encodes IGF-1 and is delivered by intrapancreatic injection; or KT-Af22, which encodes a GLP-1R...
...Transhuman Capital CEO: Shankar Ramaswamy Patents: Undisclosed Targets GCK (GK) - Glucokinase GLP-1R 9GLP1R) - Glucagon-like peptide-1 receptor...
BioCentury | May 13, 2020
Product Development

Phase III obesity data show Novo’s semaglutide nearing threshold to replace gastric bypass surgery

...week 20, escalating doses up to 2.4 mg once weekly of the long-acting glucagon-like peptide-1 receptor (GLP-1R; GLP1R...
...see “ Novo’s Year of Obesity ” ). Novo already markets Saxenda -- the only GLP-1R...
...NASH Therapies ” ). Sandi Wong, Assistant Editor Ozempic (Brand), NN9535 (Compound #), subcutaneous semaglutide (Informal) Novo Nordisk A/S Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)...
Items per page:
1 - 10 of 1305